← Back to Search

Other

Long-term Safety of Iclepertin for Schizophrenia

Phase 3
Recruiting
Research Sponsored by Boehringer Ingelheim
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Clinically stable outpatients diagnosed with schizophrenia (as per DSM-5)
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 1 year
Awards & highlights

Study Summary

This trial is for people with schizophrenia who have taken part in previous studies. The purpose is to see if they can tolerate a medicine called BI 425809 in the long term. They take it once a day for a year, plus their normal medication. They have 13 visits and 9 phone calls with the study team.

Who is the study for?
This trial is for adults with schizophrenia who previously participated in a CONNEX study. They must be clinically stable, use effective birth control if applicable, and have a regular caregiver or partner to interact with them. People can't join if they've had repeated positive drug screens, developed conditions other than schizophrenia that would interfere with the trial, or shown severe suicidal behavior recently.Check my eligibility
What is being tested?
The study tests the long-term safety of Iclepertin tablets taken daily for one year by people with schizophrenia while continuing their normal medication. Participants will visit the study site approximately 13 times and receive around 9 calls from researchers over slightly more than a year.See study design
What are the potential side effects?
While specific side effects are not listed here, participants' health problems will be monitored throughout the study to assess how well they tolerate Iclepertin over an extended period.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
I have been diagnosed with schizophrenia and am stable.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 1 year
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 1 year for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Occurrence of treatment emergent adverse events (TEAEs)
Secondary outcome measures
Change from baseline in Clinical Global Impressions - Severity (CGI-S) to end of treatment (EOT)
Change from baseline in Haemoglobin (Hb) to EOT

Side effects data

From 2019 Phase 2 trial • 611 Patients • NCT02788513
5%
Headache
5%
Nausea
3%
Dizziness
2%
Nasopharyngitis
2%
Fall
1%
Atrial flutter
1%
Transient ischaemic attack
1%
Pancreatitis acute
1%
Pneumonia
100%
80%
60%
40%
20%
0%
Study treatment Arm
2 mg BI 425809
5 mg BI 425809
10 mg BI 425809
25 mg BI 425809
Placebo Group

Trial Design

1Treatment groups
Experimental Treatment
Group I: Patients with cognitive impairment due to schizophreniaExperimental Treatment1 Intervention

Find a Location

Who is running the clinical trial?

Boehringer IngelheimLead Sponsor
2,507 Previous Clinical Trials
11,339,173 Total Patients Enrolled
14 Trials studying Schizophrenia
4,201 Patients Enrolled for Schizophrenia

Media Library

BI 425809 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05211947 — Phase 3
Schizophrenia Research Study Groups: Patients with cognitive impairment due to schizophrenia
Schizophrenia Clinical Trial 2023: BI 425809 Highlights & Side Effects. Trial Name: NCT05211947 — Phase 3
BI 425809 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05211947 — Phase 3
Schizophrenia Patient Testimony for trial: Trial Name: NCT05211947 — Phase 3

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Does the age limit for this clinical trial end at 75 years old?

"The target participants for this clinical study are adults aged 18 to 51 years old."

Answered by AI

What is the regulatorystatus of BI 425809?

"BI 425809's safety is estimated to be a 3. This is because it has reached Phase 3 clinical trials, meaning that not only does some data support its efficacy but that there have been multiple rounds of tests affirming its safety."

Answered by AI

Who else is applying?

What state do they live in?
Texas
What portion of applicants met pre-screening criteria?
Did not meet criteria
Met criteria
How many prior treatments have patients received?
3+
What site did they apply to?
Ben Taub General Hospital
InSite Clinical Research
American Medical Research

Why did patients apply to this trial?

I'm in a seemingly endless downward spiral with less and less hope for my existence.
PatientReceived 1 prior treatment
Recent research and studies
clinicaltrials.govStudy
A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study
2022. "A Study to Test Long-term Safety of Iclepertin in People With Schizophrenia Who Took Part in a Previous CONNEX Study". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05211947.
All > Schizophrenia
~626 spots leftby Feb 2026
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top